PEPTIDE, COMPLEX OF PEPTIDE AND siRNA, AND METHODS OF USE THEREOF

US2020190518A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2020190518-A1
Application numberUS-202016751783-A
CountryUS
Kind codeA1
Filing dateJan 24, 2020
Priority dateDec 18, 2013
Publication dateJun 18, 2020
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A series of peptides and a peptide-siRNA complex are disclosed, wherein the peptide based complex effectively enhances delivery of siRNA molecules into the cells and release of siRNA in the cell, and improves siRNA mediated gene silencing efficiency of cellular targets. Pharmaceutical compositions that include the complex, as well as a use of the complex in the gene therapy field, are also disclosed.

First claim

Opening claim text (preview).

What is claimed is: 1 . A peptide having the sequence CH 3 (CH 2 ) 16 CONH-B-CONH 2 , wherein B is SEQ ID NO:4 or 5. 2 . A complex comprising: a cargo molecule; and a peptide having the sequence CH 3 (CH 2 ) 16 CONH-B-CONH 2 , wherein B is SEQ ID NO:4 or 5. 3 . The complex according to claim 2 , wherein the cargo molecule and the peptide are coupled non-covalently. 4 . The complex according to claim 2 , wherein the particle size of the complex is in a range of from 20 nm to 999 nm. 5 . The complex according to claim 2 , wherein the cargo molecule is a nucleic acid. 6 . The complex according to claim 5 , wherein the nucleic acid is a short interfering RNA (siRNA). 7 . The complex according to claim 6 , wherein the siRNA is complexed with the peptide at a molar ratio within a range of from 1:1 to 80:1. 8 . The complex according to claim 6 , wherein the siRNA is complexed with the peptide at a molar ratio of 20:1. 9 . The complex according to claim 6 , wherein the siRNA is complexed with the peptide at a molar ratio of 40:1. 10 . The complex according to claim 6 , wherein the siRNA is complexed with the peptide at a molar ratio of 60:1. 11 . A pharmaceutical composition containing a complex comprising: a cargo molecule; and a peptide having the sequence CH 3 (CH 2 ) 16 CONH-B-CONH 2 , wherein B is SEQ ID NO:4 or 5. 12 . A kit used to deliver drugs to a patient, wherein the kit comprises: a pharmaceutical composition comprising a complex comprising: a cargo molecule; and a peptide having the sequence CH 3 (CH 2 ) 16 CONH-B-CONH 2 , wherein B is SEQ ID NO:4 or 5; one or more electrolytes; one or more buffers; a delivery device; and a container adapted to mix one or more other agents together. 13 . The kit according to claim 12 , wherein the cargo molecule and the peptide are coupled non-covalently. 14 . The kit according to claim 12 , wherein the particle size of the complex is in a range of from 20 nm to 999 nm. 15 . The kit according to claim 12 , wherein the cargo molecule is a nucleic acid. 16 . The kit according to claim 15 , wherein the nucleic acid is a short interfering RNA (siRNA). 17 . The kit according to claim 16 , wherein the siRNA is complexed with the peptide at a molar ratio within a range of from 1:1 to 80:1. 18 . The kit according to claim 16 , wherein the siRNA is complexed with the peptide at a molar ratio in a range of from 20:1 to 60:1. 19 . The kit according to claim 16 , wherein the siRNA is complexed with the peptide at a molar ratio of 20:1 or 40:1. 20 . A method, comprising: delivering the pharmaceutical composition of claim 11 to a patient.

Assignees

Inventors

Classifications

  • A61K47/42Primary

    Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34) · CPC title

  • Double-stranded nucleic acids or oligonucleotides · CPC title

  • Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation · CPC title

  • from mammals · CPC title

  • interfering nucleic acids [NA] · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2020190518A1 cover?
A series of peptides and a peptide-siRNA complex are disclosed, wherein the peptide based complex effectively enhances delivery of siRNA molecules into the cells and release of siRNA in the cell, and improves siRNA mediated gene silencing efficiency of cellular targets. Pharmaceutical compositions that include the complex, as well as a use of the complex in the gene therapy field, are also disc…
Who is the assignee on this patent?
Chen Pu, Positec Power Tools Suzhou Co Ltd
What technology area does this patent fall under?
Primary CPC classification A61K47/42. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Thu Jun 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).